S&P 500   4,279.67 (-0.20%)
DOW   33,389.82 (-0.35%)
QQQ   360.50 (+0.62%)
AAPL   173.44 (+1.30%)
MSFT   317.68 (+0.61%)
META   304.67 (+1.49%)
GOOGL   132.85 (+1.52%)
AMZN   128.67 (+1.22%)
TSLA   250.02 (-0.08%)
NVDA   448.75 (+3.16%)
NIO   8.77 (-2.99%)
BABA   86.02 (-0.83%)
AMD   102.75 (-0.07%)
T   14.90 (-0.80%)
F   12.39 (-0.24%)
MU   68.01 (-0.03%)
CGC   0.78 (-0.15%)
GE   109.27 (-1.16%)
DIS   81.23 (+0.22%)
AMC   8.07 (+1.00%)
PFE   33.27 (+0.30%)
PYPL   59.28 (+1.40%)
NFLX   381.36 (+1.00%)
S&P 500   4,279.67 (-0.20%)
DOW   33,389.82 (-0.35%)
QQQ   360.50 (+0.62%)
AAPL   173.44 (+1.30%)
MSFT   317.68 (+0.61%)
META   304.67 (+1.49%)
GOOGL   132.85 (+1.52%)
AMZN   128.67 (+1.22%)
TSLA   250.02 (-0.08%)
NVDA   448.75 (+3.16%)
NIO   8.77 (-2.99%)
BABA   86.02 (-0.83%)
AMD   102.75 (-0.07%)
T   14.90 (-0.80%)
F   12.39 (-0.24%)
MU   68.01 (-0.03%)
CGC   0.78 (-0.15%)
GE   109.27 (-1.16%)
DIS   81.23 (+0.22%)
AMC   8.07 (+1.00%)
PFE   33.27 (+0.30%)
PYPL   59.28 (+1.40%)
NFLX   381.36 (+1.00%)
S&P 500   4,279.67 (-0.20%)
DOW   33,389.82 (-0.35%)
QQQ   360.50 (+0.62%)
AAPL   173.44 (+1.30%)
MSFT   317.68 (+0.61%)
META   304.67 (+1.49%)
GOOGL   132.85 (+1.52%)
AMZN   128.67 (+1.22%)
TSLA   250.02 (-0.08%)
NVDA   448.75 (+3.16%)
NIO   8.77 (-2.99%)
BABA   86.02 (-0.83%)
AMD   102.75 (-0.07%)
T   14.90 (-0.80%)
F   12.39 (-0.24%)
MU   68.01 (-0.03%)
CGC   0.78 (-0.15%)
GE   109.27 (-1.16%)
DIS   81.23 (+0.22%)
AMC   8.07 (+1.00%)
PFE   33.27 (+0.30%)
PYPL   59.28 (+1.40%)
NFLX   381.36 (+1.00%)
S&P 500   4,279.67 (-0.20%)
DOW   33,389.82 (-0.35%)
QQQ   360.50 (+0.62%)
AAPL   173.44 (+1.30%)
MSFT   317.68 (+0.61%)
META   304.67 (+1.49%)
GOOGL   132.85 (+1.52%)
AMZN   128.67 (+1.22%)
TSLA   250.02 (-0.08%)
NVDA   448.75 (+3.16%)
NIO   8.77 (-2.99%)
BABA   86.02 (-0.83%)
AMD   102.75 (-0.07%)
T   14.90 (-0.80%)
F   12.39 (-0.24%)
MU   68.01 (-0.03%)
CGC   0.78 (-0.15%)
GE   109.27 (-1.16%)
DIS   81.23 (+0.22%)
AMC   8.07 (+1.00%)
PFE   33.27 (+0.30%)
PYPL   59.28 (+1.40%)
NFLX   381.36 (+1.00%)

Arcellx (ACLX) Stock Forecast, Price & News

$35.15
-0.73 (-2.03%)
(As of 10:14 AM ET)
Compare
Today's Range
$35.15
$36.00
50-Day Range
$33.06
$37.40
52-Week Range
$16.97
$48.92
Volume
18,133 shs
Average Volume
494,991 shs
Market Capitalization
$1.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.42

Arcellx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
48.9% Upside
$53.42 Price Target
Short Interest
Bearish
17.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Arcellx in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$201,390 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.19) to ($1.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

669th out of 969 stocks

Biological Products, Except Diagnostic Industry

105th out of 162 stocks


ACLX stock logo

About Arcellx (NASDAQ:ACLX) Stock

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

ACLX Price History

ACLX Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Should You be Bullish on Arcellx (ACLX)?
Analyst Ratings for Arcellx
See More Headlines
Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

ACLX Company Calendar

Last Earnings
8/14/2023
Today
10/01/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACLX
Fax
N/A
Employees
98
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.42
High Stock Price Forecast
$104.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+48.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-188,680,000.00
Pretax Margin
-568.13%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.68 per share

Miscellaneous

Free Float
45,525,000
Market Cap
$1.74 billion
Optionable
Not Optionable
Beta
-0.68
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Rami Elghandour (Age 44)
    Chairman, CEO & Pres
    Comp: $1.02M
  • Ms. Michelle Lim Gilson (Age 30)
    Chief Financial Officer
    Comp: $832.8k
  • Dr. Christopher R. Heery M.D. (Age 43)
    Chief Medical Officer
    Comp: $688.55k
  • Mr. Michael Dombeck M.B.A.
    Chief Operating Officer
  • Mr. Narinderjeet Singh M.S. (Age 51)
    Chief Technical Officer
  • Mr. David Tice Ph.D. (Age 52)
    Chief Scientific Officer
  • Ms. Myesha Lacy
    VP of Investor Relations
  • Ms. Maryam Abdul-Kareem J.D.
    M.S., Gen. Counsel
  • Ms. Kate Aiken
    Chief People Officer
  • Mr. Neeraj P. Teotia (Age 48)
    Chief Commercial Officer













ACLX Stock - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings
or view top-rated stocks.

What is Arcellx's stock price forecast for 2023?

10 analysts have issued 12 month target prices for Arcellx's stock. Their ACLX share price forecasts range from $39.00 to $104.00. On average, they expect the company's share price to reach $53.42 in the next year. This suggests a possible upside of 48.9% from the stock's current price.
View analysts price targets for ACLX
or view top-rated stocks among Wall Street analysts.

How have ACLX shares performed in 2023?

Arcellx's stock was trading at $30.98 at the start of the year. Since then, ACLX shares have increased by 15.8% and is now trading at $35.88.
View the best growth stocks for 2023 here
.

Are investors shorting Arcellx?

Arcellx saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 6,200,000 shares, a decrease of 6.1% from the August 31st total of 6,600,000 shares. Based on an average daily volume of 440,500 shares, the short-interest ratio is presently 14.1 days. Approximately 17.7% of the company's shares are sold short.
View Arcellx's Short Interest
.

When is Arcellx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ACLX earnings forecast
.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) posted its quarterly earnings results on Monday, August, 14th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.18. The business earned $14.30 million during the quarter, compared to the consensus estimate of $82.38 million.

What ETFs hold Arcellx's stock?

ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Fidelity Disruptive Medicine ETF (FMED).

When did Arcellx IPO?

(ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at a price of $15.00-$17.00 per share.

What is Arcellx's stock symbol?

Arcellx trades on the NASDAQ under the ticker symbol "ACLX."

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcellx's stock price today?

One share of ACLX stock can currently be purchased for approximately $35.88.

How much money does Arcellx make?

Arcellx (NASDAQ:ACLX) has a market capitalization of $1.74 billion. The company earns $-188,680,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis.

How can I contact Arcellx?

The official website for the company is arcellx.com. The company can be reached via phone at 240-327-0603 or via email at ir@arcellx.com.

This page (NASDAQ:ACLX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -